Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.
Publication
, Journal Article
Batra, V; Maris, JM; Kang, MH; Reynolds, CP; Houghton, PJ; Alexander, D; Kolb, EA; Gorlick, R; Keir, ST; Carol, H; Lock, R; Billups, CA; Smith, MA
Published in: Pediatr Blood Cancer
October 2012
The PIM kinase inhibitor, SGI-1776, was tested against the PPTP in vitro (1.0 nM-10 µM) and in vivo panels (148 mg/kg daily × 5 days for 3 weeks). SGI-1776 exhibited cytotoxic activity in vitro with a median relative IC(50) of 3.1 µM. SGI-1776 induced significant differences in EFS distribution in vivo in 9 of 31 solid tumor xenografts and in 1 of 8 of the evaluable ALL xenografts. SGI-1776 induced tumor growth inhibition meeting criteria for intermediate EFS T/C activity in 1 of 39 evaluable models. In contrast, SGI-1776 induced complete responses of subcutaneous MV4;11 (B myeloid leukemia).
Duke Scholars
Published In
Pediatr Blood Cancer
DOI
EISSN
1545-5017
Publication Date
October 2012
Volume
59
Issue
4
Start / End Page
749 / 752
Location
United States
Related Subject Headings
- Xenograft Model Antitumor Assays
- Pyridazines
- Proto-Oncogene Proteins c-pim-1
- Phosphoproteins
- Oncology & Carcinogenesis
- Neoplasms
- Mice, SCID
- Mice, Inbred NOD
- Mice
- Imidazoles
Citation
APA
Chicago
ICMJE
MLA
NLM
Batra, V., Maris, J. M., Kang, M. H., Reynolds, C. P., Houghton, P. J., Alexander, D., … Smith, M. A. (2012). Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer, 59(4), 749–752. https://doi.org/10.1002/pbc.23364
Batra, Vandana, John M. Maris, Min H. Kang, C Patrick Reynolds, Peter J. Houghton, Denise Alexander, E Anders Kolb, et al. “Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.” Pediatr Blood Cancer 59, no. 4 (October 2012): 749–52. https://doi.org/10.1002/pbc.23364.
Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, et al. Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Oct;59(4):749–52.
Batra, Vandana, et al. “Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.” Pediatr Blood Cancer, vol. 59, no. 4, Oct. 2012, pp. 749–52. Pubmed, doi:10.1002/pbc.23364.
Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MA. Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Oct;59(4):749–752.
Published In
Pediatr Blood Cancer
DOI
EISSN
1545-5017
Publication Date
October 2012
Volume
59
Issue
4
Start / End Page
749 / 752
Location
United States
Related Subject Headings
- Xenograft Model Antitumor Assays
- Pyridazines
- Proto-Oncogene Proteins c-pim-1
- Phosphoproteins
- Oncology & Carcinogenesis
- Neoplasms
- Mice, SCID
- Mice, Inbred NOD
- Mice
- Imidazoles